Veno-venous extracorporeal membrane oxygenation (vv-ECMO) for severe respiratory failure in adult cancer patients: a retrospective multicenter analysis.

PURPOSE: The question of whether cancer patients with severe respiratory failure benefit from veno-venous extracorporeal membrane oxygenation (vv-ECMO) remains unanswered. We, therefore, analyzed clinical characteristics and outcomes of a large cohort of cancer patients treated with vv-ECMO with the aim to identify prognostic factors.
METHODS: 297 cancer patients from 19 German and Austrian hospitals who underwent vv-ECMO between 2009 and 2019 were retrospectively analyzed. A multivariable cox proportional hazards analysis for overall survival was performed. In addition, a propensity score-matched analysis and a latent class analysis were conducted.
RESULTS: Patients had a median age of 56 (IQR 44-65) years and 214 (72%) were males. 159 (54%) had a solid tumor and 138 (47%) a hematologic malignancy. The 60-day overall survival rate was 26.8% (95% CI 22.1-32.4%). Low platelet count (HR 0.997, 95% CI 0.996-0.999; p = 0.0001 per 1000 platelets/µl), elevated lactate levels (HR 1.048, 95% CI 1.012-1.084; p = 0.0077), and disease status (progressive disease [HR 1.871, 95% CI 1.081-3.238; p = 0.0253], newly diagnosed [HR 1.571, 95% CI 1.044-2.364; p = 0.0304]) were independent adverse prognostic factors for overall survival. A propensity score-matched analysis with patients who did not receive ECMO treatment showed no significant survival advantage for treatment with ECMO.
CONCLUSION: The overall survival of cancer patients who require vv-ECMO is poor. This study shows that the value of vv-ECMO in cancer patients with respiratory failure is still unclear and further research is needed. The risk factors identified in the present analysis may help to better select patients who may benefit from vv-ECMO.

Take-home message

Introduction

Cancer patients are at increased risk for the development of respiratory failure, either due to the underlying malignancy or due to cancer treatment-related complications [1]. Respiratory failure represents the most common cause for intensive care unit (ICU) admission among patients with a malignancy [2-5]. Despite substantial improvements made in recent years, mortality attributable to acute respiratory failure remains high in this patient population [6].

Acute respiratory failure and acute respiratory distress syndrome (ARDS) are associated with a mortality rate between 28 and 50% [7, 8]. Despite improvements in recent years, mortality in patients with cancer remains to be worse [9]. Veno-venous extracorporeal membrane oxygenation (vv-ECMO) is a treatment option for patients with severe ARDS in whom conventional mechanical ventilation fails [10-12]. Vv-ECMO can serve as an artificial lung, providing extracorporeal gas exchange to maintain adequate oxygenation and carbon dioxide removal with the aim to minimize ventilator-induced lung injury until the cause of severe respiratory failure has resolved. Over the last decade, technological advances of ECMO circuits and improvements in the clinical management have resulted in better overall outcomes in patients undergoing vv-ECMO [13-15]. Recent data from the registry of the Extracorporeal Life Support Organization (ELSO) indicated a hospital discharge rate of 58% among non-cancer patients with severe ARDS receiving vv-ECMO [16].

Despite these improvements, the selection of patients eligible for vv-ECMO is an ongoing controversy. This is especially true for cancer patients given the prognostic uncertainty with regard to the underlying malignancy, the increased rate of infections relative to the general ICU population, and a high risk of severe vv-ECMO-related adverse events [17-21]. Consequently, the Guideline from the Extracorporeal Life Support Organization (ELSO) includes immunosuppression as relative contraindication for the application of vv-ECMO [22]. Data on the use of vv-ECMO in cancer patients are limited. We, therefore, conducted a large multicenter retrospective study to describe clinical characteristics, outcomes and prognostic factors of cancer patients treated with vv-ECMO.

Patients and methods

Patients

Cancer patients ≥ 18 years, with acute hypoxemic respiratory failure, who underwent vv-ECMO in 17 German and 2 Austrian hospitals between 1 January, 2009 through 31 December, 2019 were included in this retrospective multicenter study. Patients were eligible if they had been diagnosed with cancer within 5 years prior to the start of vv-ECMO treatment or if cancer was newly diagnosed with full confirmation during vv-ECMO treatment. All patients in this latter category were diagnosed with a malignant disease prior to initiation of ECMO either by imaging and/or initial histologic workup tumor tissue samples but were either missing final confirmation of their precise tumor diagnosis and/or had not initiated treatment yet. In none of the included patients was the cancer diagnosis made after ECMO initiation as a chance finding.

The study was conducted in accordance with the amended Declaration of Helsinki 2013. The study protocol was approved by the Institutional Review Board of the University of Cologne. Given the retrospective nature and the non-interventional design of the study, informed consent was waived.

Data

Age, gender, type and stage of the malignancy, date of diagnosis, type and date of cancer therapies (i.e., chemo-, immuno-, or radiotherapy, autologous or allogeneic stem cell transplantation) as well as the remission status were recorded (for details see Supplementary Information methods). A modified Charlson Comorbidity Index (mCCI) (excluding age and cancer diagnosis) was assessed to account for concurrent or preexisting conditions. Arterial blood gas parameters (pH, paO2 and paCO2, lactate), P/F ratio and laboratory tests including white blood cell count, platelet count, and hemoglobin, were also recorded. In addition, the following variables were assessed: vasopressor use, transfused blood products (platelets and packed red blood cells (PRBC)), duration of vv-ECMO, duration of mechanical ventilation, length of ICU and hospital stay, other procedure-related complications (trauma or bleeding related to cannula insertion, clotting events), severe bleeding complications (according to the International Society of Thrombosis and Haemostasis (ISTH) (at least two units of PRBC, surgical interventions or intracerebral hemorrhage [23]), ICU and hospital survival, time of death, if applicable, as well as time of the last visit.

The decision to withdraw/withhold ECMO support or other life-sustaining therapies was made in accordance with the German Society of Hematology and Medical Oncology (DGHO) and Austrian Society of Hematology and Oncology (OeGHO) consensus guidelines for cancer patients requiring intensive care support [5].

In addition to the data from the primary cohort, we used data from the EFRAIM study, a multinational prospective cohort study, which enrolled 1611 immunocompromised patients with acute hypoxemic respiratory failure [24]. Inclusion criteria were ≥ 18 years; acute hypoxemic respiratory failure; need for more than 6 L/min oxygen; respiratory symptom duration less than 72 h and non-AIDS-related immune deficiency defined as hematologic malignancy or solid tumor (active or in remission for less than 5 years, including recipients of autologous or allogeneic stem cell transplantation). This study evaluated the effects of the initial management strategy on patient outcome, i.e., endotracheal intubation rate and mortality. 51.9% and 35.2% of the patients enrolled in the study had a hematologic malignancy or a solid tumor, respectively.

Statistical analysis

Baseline categorical variables were reported as counts and percentages and were compared using the chi-square test. Baseline continuous variables were reported as medians and interquartile ranges (IQR) and were compared with the Mann–Whitney U-test. Overall survival was described with Kaplan–Meier survival curves, and the comparisons between groups were performed using the log-rank test. Model-based multiple imputation was used to account for missing values of variables. Missing data were imputed using a random forest algorithm.

Multivariable hierarchical models with random intercept per center were used to identify factors independently associated with survival. The results are reported using adjusted odds ratios (OR) for clinical covariates with 95%-confidence intervals (CI). The multivariable mixed-effect Cox proportional hazards models and generalized linear mixed-effect models were computed in R using the coxme and lme4 package, respectively. Sensitivity analysis was conducted and confirmed robustness of the results.

To compare the outcome of our cohort with patients managed without the use of ECMO, a propensity score-matched analysis was performed (see Supplementary Information: Propensity score matching). Latent class analysis (LCA) was used to derive latent subgroups within our patient cohort (see Supplementary Information: Latent class analysis).

All p values are two sided. P values < 0.05 were considered statistically significant, without correction for multiple testing. Analyses were performed with R software, version 4.0.3 (R Foundation).

Results

A total of 297 patients were included in the study. Baseline characteristics are summarized in Table 1. There were significant clinical differences between patients with hematologic malignancies and solid tumors (Table 1). Median baseline PaO2/FiO2 ratio was 71 mmHg [IQR 54–98 mmHg]. The PaO2/FiO2 ratio was lower in the group of patients with hematologic malignancies (67 mmHg [54–89 mmHg] versus 73 mmHg [59–104 mmHg]; p = 0.015). The median time from endotracheal intubation to vv-ECMO initiation was 2 days (IQR 0.65–8.62 days). Before vv-ECMO vasopressor support was necessary in 92.6% of patients and 16.2% required renal replacement therapy; 42 (14.1%) patients had undergone cardiopulmonary resuscitation (CPR) within 10 days before vv-ECMO was initiated.

Table 1

Baseline Characteristics and comparison between patients with hematologic malignancies and solid tumors

	Overall	Hematologic malignancies	Solid tumors	p-value
No. of patients (%)	297	138 (46.4)	159 (53.5)
Age (median [IQR])	56 [44–65]	48 [35.2–58.7]	59 [52.5–67]	< 0.001
Sex, male (%)	214 (72.1)	99 (71.7)	115 (72.3)
Leading cause for ICU admission
Respiratory failure	203 (68.4)	110 (79.7)	93 (58.5)	< 0.001
Surgery	41 (13.8)	2 (1.4)	39 (24.5)
Non-pulmonary infection	25 (8.4)	12 (8.7)	13 (8.2)
Cardiac event	2 (0.7)	0 (0)	2 (1.3)
Other	26 (8.8)	14 (10.1)	12 (7.5)
Reason for vv-ECMO (%)
Respiratory failure	284 (95.6)	138 (100)	146 (91.9)	0.003
ECMO-facilitated surgery	13 (4.4)	0 (0)	13 (8.1)
RESP score (median [IQR])	− 1 [− 3, 2]	0 [− 2–2]	− 1 [− 4–1]	< 0.001
P/F ratio (median [IQR])	70.5 [54.5, 98.26]	67.05 [53.78–89.37]	73.33 [58.6–103.97]	0.017
Time between intubation and vv-ECMO (in days) (median [IQR])	2 [0, 8]	1.5 [0, 7]	3 [0.5, 9]	0.051
Noradrenalin equivalents (median [IQR])	0.33 [0.1, 0.9]	0.34 [0.12–0.96]	0.3 [0.1–0.86]	0.583
Vasopressors before vv-ECMO	275 (92.6)	129 (93.5)	146 (91.8)	0.748
Renal replacement therapy before vv-ECMO	48 (16.2)	25 (18.1)	23 (14.5)	0.487
Mechanical ventilation last 180d	60 (20.2)	8 (5.8)	52 (32.7)	< 0.001
Cardiopulmonary resuscitation before vv-ECMO	42 (14.1)	15 (10.9)	27 (17)	0.180
mCCI total (median [IQR])	0 [0–1]	0 [0–1]	1 [0–2]	0.003
Disease status at admission to ICU (%)
CR	133 (44.8)	58 (42)	75 (47.2)	0.697
Newly diagnosed	56 (18.9)	30 (21.7)	26 (16.4)
PR/Controlled	70 (23.6)	33 (23.9)	37 (23.3)
Progression	22 (7.4)	11 (8)	11 (6.9)
Unknown	16 (5.4)	6 (4.3)	10 (6.3)
Cancer treatment (chemotherapy, radiotherapy, immunotherapy) within 90 days before vv-ECMO initiation	144 (48.5)	85 (61.6)	59 (37.1)	< 0.001
Previous autologous HSCT	13 (4.4)	13 (9.4)	0 (0)	< 0.001
Previous allogeneic HSCT	50 (16.8)	50 (36.2)	0 (0)	< 0.001
GVHD on admission to ICU	23 (7.7)	23 (16.7)	0 (0)	< 0.001
Leukocytes G/L (median [IQR])	12.39 [5, 18.2]	6.08 [1.81–13.46]	14.86 [11.25–20.1]	< 0.001
Neutropenia (< 500/microL)	42 (14.1)	38 (27.5)	4 (2.5)	< 0.001
Hemoglobin g/dl (median [IQR])	9.28 [8.3–10.2]	9.1 [8.3–10.2]	9.34 [8.4–10.08]	0.323
Platelets G/L (median [IQR])	135 [44–242]	48 [21.25–135]	200 [126.53–313]	< 0.001
Creatinine mg/dl (median [IQR])	1.15 [0.8–1.7]	1.23 [0.75–1.91]	1.12 [0.86–1.63]	0.847
Lactate (mmol/l)	2.07 [1.33–4.4]	2 [1.33–4.77]	2.1 [1.33–3.9]	0.411

Data are presented as n (%) for categorical variables and median (IQR) for continuous variables

ICU intensive care unit, mCCI modified Charlson Comorbidity Index (CCI) (excluded age and cancer diagnosis), HSCT hematopoietic stem cell transplantation, RESP Respiratory ECMO Survival Prediction Score, CR complete remission, PR partial remission, GVHD Graft versus host disease

The median follow-up was 182 days (95% CI 115–391 days). The 60-day overall survival for the entire study population was 26.8% (95% CI 22.1–32.4%). Baseline clinical characteristics that were associated with worse survival in multivariable analysis included disease status (newly diagnosed: HR 1.571 (95% CI 1.044–2.364; p = 0.0304); progressive disease: HR 1.871 (95% CI 1.081–3.238; p = 0.0253)), lower platelet counts (HR 0.997 (95% CI 0.996–0.999; p = 0.0001 per 1000 platelets/µl) and elevated serum lactate (HR 1.048 (95% CI 1.012–1.084; p = 0.0077)) (Fig. 1, Supplementary Information Fig. 1).

Fig. 1

Forest plots summarizing the results of the multivariate analysis for all patients. Shown are the adjusted hazard ratios for overall survival and 95% confidence intervals. (Abbreviations: mCCI modified Charlson Comorbidity Index (CCI) (excluded age and cancer diagnosis); GVHD Graft versus host disease; HSCT hematopoietic stem cell transplantation; RESP Score Respiratory ECMO Survival Prediction Score; CPR Cardiopulmonary Resuscitation)

An additional prognostic factor in patients with hematologic malignancies was serum lactate at baseline, a well-established prognostic factor in critically ill patients [35, 36]. In patients with solid tumors, only serum creatinine had independent prognostic impact in addition to platelet count. This finding in cancer patients with solid tumors is in line with many other studies on a variety of critically ill patients showing that decreased renal function is associated with worse outcome [37, 38].

Patients with hematologic malignancies had a lower median overall survival than patients with solid tumors (Supplementary Information Fig. 2). 60-day overall survival was 23% (16.8–31.5% 95% CI) for patients with hematologic malignancies and 30% (23.6–38.1% 95% CI) for patients with solid tumors (p = 0.048). In multivariable analysis, only platelet count was associated with a decreased overall survival in both patients with hematologic malignancies (0.997 (95% CI 0.994–0.999; p = 0.0372)) and solid tumors 0.998 (95% CI 0.996–0.999; p = 0.0067) (Supplementary Information Figs. 3 and 4). In patients with hematologic malignancies, progressive disease (HR 3.642 (95% CI 1.693–7.838; p = 0.0009) and higher lactate levels (HR 1.093 (95% CI 1.040–1.149; p = 0.0004) were independent adverse prognostic factors. In addition to the platelet count, higher serum creatinine was independently associated with a lower overall survival in patients with solid tumors (HR 1.332 (95% CI 1.031–1.721; p = 0.0284).

The need of transfusion of blood products was frequent in both patient groups. 94.6% and 63% of the patients required at least one unit of PRBCs or platelet concentrate, respectively (Table 2). More than half of the patients (52.5%) received ≥ 10 PRBC units (hematologic malignancies: 52.2%; solid tumors: 52.8%; p = 0.974). Given the significantly lower platelet count at baseline, patients with hematologic malignancies more often received ≥ 10 platelet transfusions (hematologic malignancies: 39.9%; solid tumors: 9.4%; p < 0.001). ECMO-related severe bleeding occurred in 38% of patients (hematologic malignancies: 44.2%; solid tumors: 32.7%; p = 0.055). Severe bleeding was the only ECMO-related complication associated with a decreased ECMO survival (OR 0.48; 0.27–0.83 95% CI) (Supplementary Information Fig. 5). Platelet count (OR 0.99; 0.995–0.999 95% CI) and recent cancer therapy (OR 2.08; 1.1–3.92 95% CI) were identified as independent risk factors for severe bleeding (Supplementary Information Fig. 6).

Table 2

Major vv-ECMO-related complications or complications during vv-ECMO

	Overall	Hematologic malignancies	Solid tumors	p-value
No. of patients (%)	297	138 (46.4)	159 (53.5)	< 0.001
Packed red blood cells units (%)				0.974
0	16 (5.4)	8 (5.8)	8 (5)
1–5	69 (23.2)	31 (22.5)	38 (23.9)
5–10	56 (18.9)	27 (19.6)	29 (18.2)
> 10	156 (52.5)	72 (52.2)	84 (52.8)
Platelet units (%)				< 0.001
0	110 (37)	28 (20.3)	82 (51.6)
1–5	81 (27.3)	40 (29)	41 (25.8)
5–10	37 (12.5)	16 (11.6)	21 (13.2)
> 10	69 (23.2)	54 (39.1)	15 (9.4)
Severe bleeding (%)	113 (38)	61 (44.2)	52 (32.7)	0.055
Ischemic stroke (%)	11 (3.7)	4 (2.9)	7 (4.4)	0.707
vv-ECMO system changed (%)	46 (15.5)	15 (10.9)	31 (19.5)	0.059
Number of vv-ECMO system changes (%)				0.109
0	251 (84.5)	123 (89.1)	128 (80.5)
1	33 (11.1)	9 (6.5)	24 (15.1)
2	11 (3.7)	5 (3.6)	6 (3.8)
3	1 (0.3)	1 (0.7)	0 (0)
5	1 (0.3)	0 (0)	1 (0.6)
Accidental decannulation (%)	0	0 (0)	0 (0)	NA
Cardiac arrest during vv-ECMO (%)	30 (10.1)	18 (13)	12 (7.5)	0.169
Ventilator associated pneumothorax (%)	33 (11.1)	13 (9.4)	20 (12.6)	0.497

To assess whether the use of vv-ECMO in cancer patients with respiratory failure leads to outcomes that are superior to invasive mechanical ventilation alone, we compared the survival of patients from our cohort with propensity score-matched mechanically ventilated patients enrolled in the EFRAIM study [24]. 79 patients could be successfully matched to patients from the EFRAIM study. Results of propensity score-matching quality are shown in Supplementary Information Table 1. The standardized mean differences for each variable were substantially reduced after matching. After propensity score matching, there was no significant difference in the survival of patients receiving ECMO and those managed with mechanical ventilation only (p = 0.089) (Fig. 2). However, in patients with platelets above 250,000/µl, the survival of patients receiving vv-ECMO was significantly higher than in patients receiving mechanical ventilation only (p = 0.023) (Supplementary Information Fig. 7).

Fig. 2

Propensity score-matching patients receiving ECMO and those managed with mechanical ventilation (MV) only of the EFRAIM study [24]

To derive distinct patient subgroups with different trajectories within our study population, we performed LCA, a statistical method to uncover hidden subgroups in data. LCA can be used to classify patients into mutually exclusive and exhaustive subgroups of individuals, so called latent classes, based on their pattern of a set of categorical characteristics. The variables used for LCA were cancer type, age, P/F ratio, platelets, remission status, cancer therapy in the previous 30 days, and duration of mechanical ventilation prior to vv-ECMO initiation. A 2-class LCA model best described the overall patient cohort (Fig. 3a). The two classes were practically identical to the subgroups of patients with hematologic malignancies and solid tumors, confirming the clinical significance of differentiating these patient populations. Moreover, there was a statistically significant difference in survival between these two groups (Fig. 3d, Class 1 vs. Class 1 p = 0.0002). We, therefore, performed LCA separately in patients with hematologic malignancies and solid tumors (Fig. 3b, c). In both groups, a 3-class model provided the best fit to the data. The three classes divided patients with hematologic malignancies and solid tumors into similar clinical subgroups. Class 1 consisted predominantly of older patients in partial remission who recently received tumor therapy but were not severely thrombocytopenic. The patients in class 2 were mostly younger and had all recently received tumor-directed therapy. As would be expected for younger patients treated with more aggressive regimens this patient population was characterized by moderate to severe thrombocytopenia. Class 3 represented a group of predominantly older patients who were either newly diagnosed with cancer or were in complete remission and therefore mostly not receiving any form of cancer therapy. Accordingly, these patients had no to mild thrombocytopenia. Importantly, the younger thrombocytopenic patients with hematologic malignancies undergoing active cancer therapy with severe thrombocytopenia, i.e., class 2, had a worse survival than the patients in the other subgroups (Fig. 3e, Class 2 vs. Class 1 p = 0.02, Class 2 vs. Class 3 p = 0.02). None of the patients with solid tumors belonging to class 2 survived for more than 2 months after initiation of vv-ECMO (Fig. 3f, Class 2 versus Class 1 p = 0.16, Class 2 vs. Class 3 p = 0.06). However, the survival difference between class 1 and the other classes was not statistically significant.

Fig. 3

Latent class analysis and corresponding Kaplan–Meier curves for survival probability for all patients (a, d), patients with hematologic malignancies. (b, e), and patients with solid tumors (c, f). The overall patient cohort is best described by a 2-class model, which divides the cohort into patients with hematologic malignancies and solid tumors (d, Class 1 vs. Class 1 p = 0.0002) Patients with hematologic malignancies (b) are divided into three analogous classes. Class 1: patients who are more likely to be older and in partial remission with only mild thrombocytopenia. Class 2: younger patients undergoing cancer therapy with moderate to severe thrombocytopenia. Class 3: predominantly elderly patients who currently do not undergo cancer treatment because they are newly diagnosed or in complete remission and have no to mild thrombocytopenia. Class 2 had a worse survival than the patients in the other subgroups (i.e., Class 2 vs. Class 1 p = 0.02, Class 2 vs. Class 3 p = 0.02). All patients with solid tumors belonging to class 2 died within one month after initiation of vv-ECMO (c). (Abbreviations: complete remission (CR); partial remission (PR); progressive disease (PD)). Related gradiations have been color-coded in the categories

Discussion

The main findings of our analysis show that disease status, low platelet count and high lactate levels indicate a poor prognosis. The outcome of cancer patients receiving ECMO was not superior to propensity score-matched patients treated only with conventional mechanical ventilation.

Vv-ECMO represents a rescue intervention for patients with severe ARDS [25]. However, substantial uncertainty remains about the benefit of vv-ECMO for specific subgroups of patients [26, 27]. In particular, the role of vv-ECMO in cancer patients is a matter of debate. Only few studies have reported on outcomes of vv-ECMO in patients with malignant diseases [19, 28–34].

To our knowledge, the study presented here is the largest study in this patient population conducted to date. The only other larger study on this topic reported the outcome of 203 immunocompromised patients with severe ARDS on vv-ECMO including 101 patients with cancer [19]. The study by Schmidt et al. investigated immunosuppressed patients, including patients with hematologic malignancies (n = 62), solid tumors (n = 39), solid-organ transplantation (n = 27), AIDS (n = 19), and long-term use of corticosteroids/immunosuppressants (n = 56). Overall, the outcome of cancer patients receiving vv-ECMO as a rescue treatment for respiratory failure was rather poor. The overall survival of cancer patients in this study was comparable to our study (6-month overall survival of 30% vs. a 60-day overall survival of 26.8% in our study). Although the overall survival of cancer patients in our study was worse compared to patients without cancer, a significant minority of patients achieved long-term survival after vv-ECMO. Most deaths occurred in the first month after ECMO initiation. After around 60 days, the Kaplan–Meier overall survival curve reached a stable plateau (Supplementary information Fig. 1 and Fig. 2). The prognosis of patients with cancer on vv-ECMO should, therefore, not generally be regarded as futile. However, the high short-term mortality in our study indicates the need for better prognostic tools.

Even though the results are difficult to compare directly since Schmidt et al. only report the results for the overall population of immunosuppressed patients, there are important commonalities but also differences between the two studies. Identical to our study, platelet count was associated with overall survival in the study population of immunocompromised patients. Platelet count is a complex variable associated with and influenced by many clinical conditions. Potential causes for a low platelet count include myelosuppressive chemotherapy, bleeding, severe infection or sepsis, and severity of illness in many non-malignant medical conditions. Thus, in patients with cancer, platelet count can be regarded as an indicator of the general severity of illness and a risk factor for bleeding-related morbidity and mortality. Interestingly, LCA revealed that the severely thrombocytopenic patients were mostly younger cancer patients undergoing anticancer therapy. Unfortunately, even though such patients are usually aggressively treated with curative intent they seem to have a high vv-ECMO-associated mortality risk.

In addition, in the study by Schmidt et al. longer-term immunosuppression (> 30d), baseline PaCO2, and driving pressure were shown to negatively affect outcome. In contrast, in our study, the group of patients with newly diagnosed cancer, i.e., cancer patients who are immunocompromised for only a short time, had a worse prognosis.

Treatment with vv-ECMO is associated with several serious and potentially life-threatening complications. The most frequent adverse events are bleeding, mechanical problems with the ECMO circuit, and device-related infections. Less common, but also severe complications include cerebrovascular events, cardiac arrhythmias, and cardiac arrest. The complication rates observed in the present analysis differ substantially from those reported in non-cancer patients (Table 2 and Supplementary Information Fig. 5) [16, 26]. We observed a high rate of severe bleeding episodes (38%). Severe hemorrhage during ECMO was associated with increased ECMO-related mortality (Supplementary Information Fig. 5). Clinical factors that were correlated with an increased risk of bleeding were thrombocytopenia and recent chemotherapy (Supplementary Information Fig. 6). Thus, part of the negative prognostic impact of thrombocytopenia could be explained by higher risk of bleeding-related mortality during vv-ECMO, especially in combination with chemotherapy-induced vascular damage and disruption of the integrity of the skin and mucous barriers.

The provocative finding that the outcome of cancer patients receiving ECMO was not superior to propensity score-matched patients treated only with conventional mechanical ventilation, suggests that we currently have insufficient knowledge to appropriately select patients who would benefit from provision of vv-ECMO support. To improve the outcome of cancer patients with acute respiratory failure, it will be crucial to better understand which clinical characteristics are important for patient selection and how these factors affect the outcome of vv-ECMO. In this study, the presence of thrombocytopenia was consistently associated with worse outcome and should be accounted for in the decision to offer vv-ECMO support. Since increased bleeding-related complications seem to be an important contributing factor for poor outcome in thrombocytopenic patients, further improvements in coagulation and bleeding management are needed and should lead to higher rates of treatment success with vv-ECMO in cancer patients.

Furthermore, this study demonstrates that a relevant number of patients (8%) received vv-ECMO despite progression of their malignant disease at the time of ECMO initiation. The decision to initiate vv-ECMO in this setting is intriguing given that tumor progression is generally associated with a poor prognosis [36-38]. This study confirms that progressive disease indicates a very poor prognosis (Fig. 1). Only 3/22 (13%) patients with progressive disease survived. Patients with progressive disease, therefore, should not be offered vv-ECMO.

The present study has several limitations. Due to the retrospective study design, selection bias and residual confounding cannot be excluded. We included a wide variety of variables to adjust for differences in patient characteristics, but further variance remains which we were not able to account for. The hospitals included in the study were not a random sample of all hospitals performing ECMO in cancer patients. The majority were large tertiary care hospitals with experience in vv-ECMO as well as in providing care to critically ill patients with cancer and other complex conditions such as severe respiratory failure. In addition, the collected data span over a period of 10 years. Over the last decade, the management of patients with ARDS, including those undergoing vv-ECMO has improved considerably. Concurrently, there have been advances in the treatment of cancer during the study period. We therefore cannot exclude time-dependent effects that may have influenced our analysis. However, a comparison between the time periods 2009–2013 and 2014–2019 showed no major differences (Supplementary information Table 3). In the matched-pair analysis of patients treated with ECMO or mechanical ventilation only, we tried to match patients for relevant clinical characteristics. Nonetheless, despite propensity score matching, there may be additional unaccounted confounders that could affect the results of our analysis. The results of the LCA should be interpreted with caution due to the limited sample size, particularly for the subpopulations of hematologic malignancies and solid tumor.

Conclusion

The overall survival of cancer patients who require vv-ECMO is poor. This study shows that the value of vv-ECMO in cancer patients with respiratory failure is still unclear and further research is needed. Given the uncertainty regarding the value of vv-ECMO in this patient population the indication for vv-ECMO should be made by a multidisciplinary team including both intensivists and hemato-oncologists taking into account both the prognosis of the acute condition leading to ICU admission and the underlying malignancy. In this study, we identified disease status, low platelet count and high lactate levels as indicators of poor prognosis that should be accounted for in the decision to provide vv-ECMO.

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 727 KB)

Supplementary file2 (DOCX 33 KB)

The overall survival of cancer patients who require vv-ECMO is poor and, therefore, vv-ECMO should only be offered to selected patients. We identified disease status, low platelet count and high lactate levels are indicators of poor prognosis that should be accounted for in the decision to provide vv-ECMO.